SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SWOG | S1827-SCLC, MRI Surveillance +/- PCI | 1 | Y | 1 PCI + MRI brain surveillance | 668 | 114 | 35 | 17 | 8 | 2 | 0 | 05/04/2020 | 342 | 129 |
2 MRI brain surveillance | 116 | 35 | 23 | 9 | 3 | 0 | ||||||||
230 | 70 | 40 | 17 | 5 | 0 | |||||||||
S1914-NSCLC, High Risk Early Stg, SBRT +/- Atezo | 1 | Y | 1 Atezolizumab and SBRT | 480 | 201 | 85 | 47 | 22 | 11 | 1 | 08/13/2020 | 367 | 131 | |
2 SBRT | 199 | 84 | 44 | 27 | 8 | 2 | ||||||||
400 | 169 | 91 | 49 | 19 | 3 | |||||||||
S1933-NSCLC, Stg II-III, RT + Atezo | 1 | Y | 1 Hypofractionated Radiotherapy | 47 | 39 | 10 | 6 | 3 | 1 | 0 | 01/13/2021 | 117 | 43 | |
39 | 10 | 6 | 3 | 1 | 0 | |||||||||
2 | Y | 2 Atezolizumab | 30 | 7 | 5 | 1 | 1 | 0 | 01/13/2021 | |||||
30 | 7 | 5 | 1 | 1 | 0 | |||||||||
S2302-NSCLC, Stg IV or Recur, Ramu + Pembro vs SoC | 1 | Y | 1 Standard of Care (Inv. Choice) | 700 | 282 | 249 | 126 | 60 | 21 | 6 | 03/14/2023 | 467 | 192 | |
2 Ramucirumab + Pembrolizumab | 283 | 243 | 131 | 59 | 20 | 5 | ||||||||
565 | 492 | 257 | 119 | 41 | 11 | |||||||||
LUNGMAP-NSCLC, Adv, Master | 0 | N | 0 ctDNA Specimen Submission | 315 | 0 | 0 | 0 | 0 | 0 | 02/06/2019 | 419 | 178 | ||
315 | 0 | 0 | 0 | 0 | 0 | |||||||||
1 | Y | 1 Biomarker Profiling | 3434 | 311 | 158 | 84 | 33 | 6 | 02/06/2019 | |||||
3434 | 311 | 158 | 84 | 33 | 6 | |||||||||
2 | Y | 10 S1800D | 516 | 0 | 0 | 0 | 0 | 0 | ||||||
11 S1900F | 2 | 0 | 0 | 0 | 0 | 0 | ||||||||
12 S1900G | 20 | 15 | 6 | 3 | 1 | 0 | ||||||||
13 S1900K | 4 | 4 | 4 | 2 | 1 | 0 | ||||||||
2 S1400F | 31 | 0 | 0 | 0 | 0 | 0 | 02/06/2019 | |||||||
4 S1800A | 653 | 0 | 0 | 0 | 0 | 0 | ||||||||
5 S1900A | 101 | 0 | 0 | 0 | 0 | 0 | ||||||||
6 S1900B | 13 | 0 | 0 | 0 | 0 | 0 | ||||||||
7 S1900C | 101 | 0 | 0 | 0 | 0 | 0 | ||||||||
9 S1900E | 236 | 39 | 15 | 8 | 2 | 1 | ||||||||
1677 | 58 | 25 | 13 | 4 | 1 | |||||||||
3 | Y | 22 S1400F | 3 | 0 | 0 | 0 | 0 | 0 | 02/06/2019 | |||||
24 S1800A | 14 | 0 | 0 | 0 | 0 | 0 | ||||||||
26 S1900B | 1 | 0 | 0 | 0 | 0 | 0 | ||||||||
27 S1900C | 4 | 0 | 0 | 0 | 0 | 0 | ||||||||
29 S1900E | 3 | 0 | 0 | 0 | 0 | 0 | ||||||||
30 S1800D | 25 | 0 | 0 | 0 | 0 | 0 | ||||||||
31 S1900F | 1 | 0 | 0 | 0 | 0 | 0 | ||||||||
51 | 0 | 0 | 0 | 0 | 0 | |||||||||
4 | Y | 49 S1900E | 1 | 0 | 0 | 0 | 0 | 0 | 02/06/2019 | |||||
1 | 0 | 0 | 0 | 0 | 0 | |||||||||
Yes | A081801-ALCHEMIST4, ALK and EGFR negative, Chemo-IO | 1 | E | Total Registrations | 80 | 18 | 10 | 5 | 4 | 1 | 10/20/2020 | 418 | 173 | |
80 | 18 | 10 | 5 | 4 | 1 | |||||||||
A151216-ALCHEMIST0 - screening | 1 | E | Total Registrations | 977 | 27 | 8 | 2 | 2 | 1 | 12/16/2014 | 511 | 238 | ||
977 | 27 | 8 | 2 | 2 | 1 | |||||||||
EA5162-NSCLS,StgIV/IIB,EGFR exon20 insertion,AZD9291 | 1 | E | Total Registrations | 1 | 1 | 0 | 0 | 0 | 0 | 08/23/2023 | 84 | 39 | ||
1 | 1 | 0 | 0 | 0 | 0 | |||||||||
EA5182-NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291 | 1 | E | Total Registrations | 18 | 10 | 7 | 4 | 1 | 1 | 04/28/2021 | 177 | 81 | ||
18 | 10 | 7 | 4 | 1 | 1 | |||||||||
NRGLU008-Lung NSCL, StgII-III, StereoBodyRad/MedChemo | 1 | E | Total Registrations | 1 | 1 | 1 | 0 | 0 | 0 | 01/26/2024 | 34 | 14 | ||
1 | 1 | 1 | 0 | 0 | 0 | |||||||||
No | A082002-Lung, Adv, Systemic Tx +/- SBRT | 1 | E | Total Registrations | 4 | 1 | 0 | 0 | 0 | 0 | 10/12/2022 | 207 | 64 | |
4 | 1 | 0 | 0 | 0 | 0 | |||||||||
A151216-ALCHEMIST0 - screening | 0 | E | Total Registrations | 992 | 27 | 9 | 3 | 2 | 1 | 12/16/2014 | 511 | 238 | ||
992 | 27 | 9 | 3 | 2 | 1 | |||||||||
Study | Registration/Phase | Open Date | # of ACT. INSTs |
# of CURR IRBs |
---|---|---|---|---|
LUNGMAP NSCLC, Adv, Master | 5 Sub-study Assignment IV | 28-Jan-19 | 419 | 178 |